People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2022 |
| Tyme Technologies, Inc. | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2020 |
| Aptuit Intermediate Holdings, Inc. | — | Other | Pre-Seed | $467K | $10.8M | 2010 |
Timothy C. Tyson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Timothy C. Tyson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Amir Nashat | 1 | 14 |
| Srinivas Akkaraju | 1 | 10 |
| Tommy G. Thompson | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Jorge Conde | 1 | 4 |
| Stephane Bancel | 1 | 4 |
| James E. Bradner | 1 | 3 |
| Peter Wirth | 1 | 3 |
| STEVE HOFFMAN | 1 | 3 |
| Robert E. Nelsen | 1 | 3 |
| Mark Alles | 1 | 3 |
| Richard A. Young | 1 | 2 |
| John D. Clark | 1 | 2 |
| Paul B. Queally | 1 | 2 |
| David A. Roth | 1 | 2 |
| Philip Sharp | 1 | 2 |
| BRIAN T. REGAN | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.